Skip to main content

Refine your results

Filters
Date
Displaying 161 - 180 of 209

Concurring Statement of Commissioner Rebecca Kelly Slaughter in the Matter of Shop Tutors, Inc. d/b/a LendEDU

In the Matter of Shop Tutors, Inc. d/b/a LendEDU
Washington, D.C.
Date
Matter Number

182 3180

By
Rebecca Kelly Slaughter, Commissioner
Related Releases
Operators of Comparison Shopping Website Agree to Settle FTC Charges Alleging Deceptive Rankings of Financial Products and Fake Reviews

Concurring Statement of Commissioner Rebecca Kelly Slaughter in Federal Trade Commission; and State of New York v. Vyera Pharmaceuticals, LLC; Phoenixus AG; Martin Shkreli; and Kevin Mulleady

Federal Trade Commission; and State of New York v. Vyera Pharmaceuticals, LLC; Phoenixus AG; Martin Shkreli; and Kevin Mulleady
Date
By
Rebecca Kelly Slaughter, Commissioner
Related Releases
FTC and NY Attorney General Charge Vyera Pharmaceuticals, Martin Shkreli, and Other Defendants with Anticompetitive Scheme to Protect a List-Price Increase of More Than 4,000 Percent for Life-Saving Drug Daraprim

Statement of the Federal Trade Commission in the matter of Roche Holding/Spark Therapeutics

In the matter of Roche Holding/Spark Therapeutics
Date
Matter Number

191 0086

By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Commissioner;
Christine S. Wilson, Former Commissioner
Related Releases
Federal Trade Commission Closes Investigation of Roche Holding AG’s Proposed Acquisition of Spark Therapeutics, Inc.

Concurring Statement of Commissioner Rebecca Kelly Slaughter In the Matter of the University of Phoenix, Inc.

Washington, D.C.
Date
Matter Number

152 3231

By
Rebecca Kelly Slaughter, Commissioner
Related Releases
FTC Obtains Record $191 Million Settlement from University of Phoenix to Resolve FTC Charges It Used Deceptive Advertising to Attract Prospective Students

Dissenting Statement of Commissioner Rebecca Kelly Slaughter In the Matter of Bristol-Myers Squibb Company and Celgene Corporation

Washington, D.C.
Date
Matter Number

191 0061

Docket Number
C-4690
By
Rebecca Kelly Slaughter, Commissioner
Related Releases
FTC Requires Bristol-Myers Squibb Company and Celgene Corporation to Divest Psoriasis Drug Otezla as a Condition of Acquisition
FTC Approves Modifications to Bristol Meyers Squibb Divestiture Agreement

Statement of Federal Trade Commission In the Matter of Your Therapy Source, Neeraj Jindal and Sheri Yarbray

Date
By
Joseph J. Simons, Former Chairman;
Noah Joshua Phillips, Former Commissioner;
Rebecca Kelly Slaughter, Commissioner
Related Releases
FTC Approves Final Order Prohibiting Conduct by Therapist Staffing Company and Two Owners Accused of Colluding with Competitors on Compensation

Statement of Commissioner Chopra Joined by Commissioner Slaughter Regarding Sunday Riley

Date
By
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Commissioner
Related Releases
Devumi, Owner and CEO Settle FTC Charges They Sold Fake Indicators of Social Media Influence; Cosmetics Firm Sunday Riley, CEO Settle FTC Charges That Employees Posted Fake Online Reviews at CEO’s Direction

Joint Statement of Commissioners Rohit Chopra and Rebecca Kelly Slaughter in the Matter of DTE Energy/Generation Pipeline

In the Matter of DTE Energy/Generation Pipeline
Date
Matter Number

191 0068

By
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Commissioner
Related Releases
FTC Puts Conditions on NEXUS Gas Transmission, LLC’s Acquisition of Generation Pipeline LLC

Dissenting Statement of Commissioner Rebecca Kelly Slaughter in the Matter of Google LLC and YouTube, LLC

Date
By
Rebecca Kelly Slaughter, Commissioner
Related Releases
Google and YouTube Will Pay Record $170 Million for Alleged Violations of Children’s Privacy Law
Google and YouTube Will Pay Record $170 Million for Alleged Violations of Children’s Privacy Law

Statement of Commissioners Chopra and Slaughter Regarding the Federal Trade Commission Report on the Use of Section 5 to Address Off-Patent Pharmaceutical Price Spikes

Regarding the Federal Trade Commission Report on the Use of Section 5 to Address Off-Patent Pharmaceutical Price Spikes
Date
By
Rohit Chopra, Former Commissioner;
Rebecca Kelly Slaughter, Commissioner
FTC Report on Standalone Section 5 to Address High Pharmaceutical Drug and Biol…
Displaying 161 - 180 of 209

Join us at the FTC!

View our open positions

Return to top